By Sherri
Oslick —

About
Court
Report:  Each week we will report briefly on recently filed
biotech and pharma cases.

Pfizer Inc. et al. v. Mylan Inc. et al.
1:10-cv-00528; filed June 16, 2010 in the District
Court of Delaware

• Plaintiffs:  Pfizer Inc.; Pharmacia & Upjohn
Co.; Pharmacia & Upjohn Co. LLC; Sugen Inc.; C P Pharmaceuticals
International CV
• Defendants:  Mylan Inc.; Mylan Pharmaceuticals
Inc.

Infringement of U.S. Patent Nos. 6,573,293 ("Pyrrole
Substituted 2-Indolinone Protein Kinase Inhibitors," issued June 3, 2003),
7,125,905 (same title, issued October 24, 2006), and 7,211,600 ("Methods
of Modulating c-kit Tyrosine Protein Kinase Function with Indolinone Compounds,"
issued May 1, 2007) following a Paragraph IV certification as part of Mylan's
filing of an ANDA to manufacture a generic version of Pfizer's Sutent®
(sunitinib malate, used to treat gastrointestinal stromal tumor and advanced
renal cell carcinoma).  View the
complaint here.

Allergan, Inc. v. Apotex, Inc. et al.
2:10-cv-00200; filed June 15, 2010 in the Eastern
District of Texas

• Plaintiff:  Allergan, Inc.
• Defendants:  Apotex, Inc.; Apotex Corp.

Infringement of U.S. Patent Nos. 7,030,149 ("Combination
of Brimonidine Timolol For Topical Ophthalmic Use," issued April 18,
2006), 7,320,976 ("Combination of Brimonidine and Timolol For Topical
Ophthalmic Use," issued January 22, 2008), 7,323,463 (same title, issued
January 29, 2008) and 7,642,258 (same title, issued January 5, 2010) following
a Paragraph IV certification as part of Apotex's filing of an ANDA to
manufacture a generic version of Allergan's Combigan® (brimonidine
tartrate/timolol maleate ophthalmic solution, used to treat glaucoma).  View the complaint here.

Bayer Schering Pharma AG et al. v. Teva Pharmaceuticals USA,
Inc. et al.
1:10-cv-03697; filed June 15, 2010 in the Northern
District of Illinois

• Plaintiffs:  Bayer Schering Pharma AG; Bayer
Healthcare Pharmaceuticals Inc.
• Defendants:  Teva Pharmaceuticals USA, Inc.; Barr
Pharmaceuticals LLC; Barr Laboratories, Inc.

Infringement of U.S. Patent No. 5,569,652 ("Dihydrospirorenone
as an antiandrogen," issued October 29, 1996) as well as false advertising
based on defendants' manufacture and sale of its Gianvi product, a generic
version of Bayer's Yaz® (drospirenone & ethinyl estradiol, used for oral
contraception).  View the complaint here.

Abbott Laboratories et al. v. Anchen Pharmaceuticals, Inc.
2:10-cv-03015; filed June 14, 2010 in the District
Court of New Jersey

• Plaintiffs:  Abbott Laboratories; Fournier
Laboratories Ireland Ltd.
• Defendant:  Anchen Pharmaceuticals, Inc.

Infringement of U.S. Patent No. 7,259,186 ("Salts
of Fenofibric Acid and Pharmaceutical Formulations Thereof," issued August
21, 2007) following a Paragraph IV certification as part of Anchen's filing of
an ANDA to manufacture a generic version of Abbott's Trilipix® (choline
fenofibrate delayedrelease, used to treat increased triglyceride levels).  View the complaint here.

Medicis Pharmaceutical Corp. v. Mylan Inc. et al.
1:10-cv-00524; filed June 14, 2010 in the District
Court of Delaware

• Plaintiff:  Medicis Pharmaceutical Corp.
• Defendants:  Mylan Inc.; Matrix Laboratories
Ltd.

Infringement of U.S. Patent No. 5,908,838 ("Method
for the Treatment of Acne," issued June 1, 1999) following a Paragraph IV
certification as part of defendants' filing of an ANDA to manufacture a generic
version of Medics' Solodyn® (minocycline hydrochloride extended release
tablets, used to treat acne).  View
the complaint here.

Genzyme Corp. v. Anchen Pharmaceuticals Inc. et al.
1:10-cv-00512; filed June 10, 2010 in the District
Court of Delaware

• Plaintiff:  Genzyme Corp.
• Defendants:  Anchen Pharmaceuticals Inc.; Anchen
Inc.

Infringement of U.S. Patent No. 5,602,116 ("Method
for Treating and Preventing Secondary Hyperparathyroidism," issued
February 11, 1997) following a Paragraph IV certification as part of Anchen's
filing of an ANDA to manufacture a generic version of Genzyme's Hectorol®
(doxercalciferol, used to treat secondary hyperparathyroidism in patients with
chronic kidney disease).  View the
complaint here.